Kemin’s FloraGLO Legacy Continues with New Blue Light Protection Patent

636040850652417747eyehealth.jpg

14 Jul 2016 --- The United States Patent and Trademark Office has issued Kemin Industries a patent for the role of its products in protecting individuals with three common ocular disorders from blue light or light-induced damage.

The royalty-free license for these products (FloraGLO Lutein and ZeaONE Zeaxanthin, distributed by DSM as OPTISHARP Natural) will provide a ‘huge market opportunity.’
 
Kemin’s patent (US Patent No. 9,226,940 B2) allows vitamin and dietary supplement manufacturers using FloraGLO and/or ZeaONE to position their products for blue light protection. The patent specifically covers products containing ocular antioxidants including lutein and zeaxanthin employed to protect the eye from light-induced damage, particularly the damage caused by the blue wavelengths of light.
 
The patent targets individuals with presbyopia, hyperopia or astigmatism. In these three conditions, blue wavelengths of light are focused directly onto the macula, creating a higher risk for ocular damage.
 
Blue light impacts the majority of adults ages 45 and older who have presbyopia, commonly known as age-related farsightedness.
 
“Because of the widespread prevalence of presbyopia, this patent opens the door for FloraGLO and OPTISHARP Natural customers to make blue light eye protection claims when targeting consumers 45 years and older,” said Dr. Richard Roberts, Patent Inventor and Principal Manager of Scientific Affairs and Technical Services for the Human Nutrition and Health division of Kemin.
 
Nearly every source of light—whether natural or artificial—emits harmful blue wavelengths of light.
The growing prevalence of digital devices like computers, tablets and smartphones is exposing individuals to more blue light than ever before.
 
Over half of Americans use digital devices more than five hours a day and 70% use two or more devices at the same time.
 
In addition to blue light from digital devices, the use of the light emitting diode (LED) in indoor lighting is another growing source of blue light exposure. LED bulbs contain 35% blue light levels as compared to 3% levels in traditional incandescent bulbs. In North America alone, LED lighting made up a US$4.8 billion market in 2012 and is expected to make up a US$42 billion market by 2019.
 
As blue light levels and sources continue to grow, children are especially vulnerable to the effects. Blue light exposure is especially concerning for infants and young children, as nearly every child is born with hyperopia, commonly known as farsightedness. Because of the condition, they are at a higher risk for blue light and light-induced damage as their eyes develop.
 
“Children are exposed to blue light more than ever before. Believe it or not, greater than half of American children use digital devices two or more hours a day,” said Heather Richardson, Vision Platform Senior Product Manager for the Human Nutrition and Health division of Kemin. “Our patent can help customers address this growing concern and develop blue light protection products for kids.”
 
“We are pleased to be able to offer a royalty-free license of our patent to customers who are interested in marketing blue light protection products to adults 45+ and children ages 0-2,” said Anita Norian, President of the Human Nutrition and Health division of Kemin. “It is clear this will be a huge market opportunity for our customers as the concern of blue light exposure and consumer awareness grows.”

Related Articles

Nutrition & Health News

Soy, cruciferous vegetables linked to fewer breast cancer treatment side effects

11 Dec 2017 --- Consuming soy foods and cruciferous vegetables – such as cabbages, kale, collard greens, bok choy, Brussels sprouts and broccoli – may be associated with a reduction in common side effects of breast cancer treatment in breast cancer survivors, according to a team of scientists led by Georgetown Lombardi Comprehensive Cancer Center. Understanding the role of life style factors with regard to the side effects is important because diet can serve as a modifiable target for possibly reducing symptoms among breast cancer survivors.

Food Ingredients News

One in four consumers spend less than five minutes on weekday breakfast: DSM survey

07 Dec 2017 --- DSM has found that one in four consumers spend less than five minutes on breakfast on weekdays, and half of consumers spend less than 15 minutes on breakfast. The findings are some of the results of DSM’s Breakfast Insights survey, which also include suggestions that the main reason for skipping breakfast is lack of time and consumers are paying more attention to the lack of sugar in their breakfast.

Business News

Weight management program can put Type 2 diabetes into remission finds Lancet study

06 Dec 2017 --- Type 2 diabetes can be reversed following an intensive weight management program, according to a randomized trial in adults who have had the condition for up to six years, published in The Lancet. The findings lend support to the widespread use of this type of intervention in the routine care of Type 2 diabetes across health services.

Business News

Nestle acquires Atrium for US$2.3 billion, extends consumer healthcare portfolio

06 Dec 2017 --- Nestle has agreed to acquire Canadian nutritional health products manufacturer Atrium Innovations from a group of investors led by Permira Funds for US$2.3 billion in cash. Nestle notes that the move for the company, whose 2017 sales are expected to reach almost US$700 million, supports Nestle’s pursuit of growth opportunities in consumer healthcare to complement the company's focus on its high-growth food and beverage categories.

Business News

Exercise changes gut microbiota independent of diet, researchers report

05 Dec 2017 --- Exercise alone can change the composition of microbes in the gut, according to two studies – one in mice and the other in human subjects. The studies, which offer the first definitive evidence of the hypothesis, were designed to isolate exercise-induced changes from other factors – such as diet or antibiotic use – that might alter the intestinal microbiota.

More Articles
URL : http://www.nutritioninsight.com:80/news/kemins-floraglo-legacy-continues-with-new-blue-light-protection-patent.html